Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)

NCT03245840 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT03245840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03245840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Lead sponsor
Shire
Phase
Phase 3
Overall status
Terminated
Start date
October 5, 2017
Completion date
April 26, 2022
Enrollment
133 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis (eoe)